Antibodies specifically binding to IL-2 and their applications

By developing antibodies that specifically bind IL-2, the stability and matrix interference problems of existing IL-2 quantitative detection methods are solved, and efficient and accurate IL-2 detection is achieved, suitable for T cell culture and CAR-T cells. treat.

CN118515762BActive Publication Date: 2024-11-01ACROBIOSYSTEMS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410986662.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-01
Estimated Expiration
2044-07-23

AI Technical Summary

Technical Problem

The existing IL-2 quantitative detection method is not stable enough, and there are problems with large inter-plate variation coefficient and interference between different substrates, resulting in unreliable detection results.

Method used

Develop antibodies specifically binding to IL-2 and their applications, provide amino acid sequences of heavy and light chain variable regions, and use them to prepare antibodies or antigen-binding fragments that can specifically bind IL-2 to achieve high sensitivity and specificity , quantitative detection of accuracy and stability, and is not disturbed by matrix.

Benefits of technology

The detection kit developed for IL-2 can be accurately detected in different matrixes and is suitable for T cell culture and CAR-T cell therapy. The residual detection of IL-2 in the middle improves the application efficiency of cell gene therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118515762B_ABST
    Figure CN118515762B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of antibody technology, and in particular to antibodies that specifically bind to IL-2 and applications thereof. The antibody provided by the present invention can specifically bind to IL-2, has no cross-reaction with other cytokines such as interleukins, and has a high affinity for IL-2, and performs well in the quantitative detection of IL-2. The IL-2 detection kit based on the antibody can realize the quantitative detection of IL-2 in different matrix samples, is not interfered by the matrix, has high sensitivity, specificity, accuracy and precision, is simple and fast to operate, has low cost, and has good application value in the quantitative detection of IL-2.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of antibody technology, and in particular to antibodies specifically binding to IL-2 and applications thereof. Background Art

[0002] Interleukin-2 (IL-2) was first reported in 1976. For decades, IL-2 has been considered a key molecule to promote T cell proliferation and differentiation, and is therefore also known as T cell growth factor.

[0003] Chimeric antigen receptor T cell (CAR-T) therapy involves genetically engineering T cells (autologous or allogeneic) to express chimeric antigen receptors against specific tumor antigens. Throughout the process, successful T cell expansion is critical to ensure that there are enough cells available for treatment. IL-2 is the main cytokine used for CAR-T therapy and plays a vital role in the proliferation and functional effects of T cells.

[0004] IL-2 is one of the most important cytokines in T cell activation and is mainly produced by CD4+ T cells. 4+ Th cell secretion, NK, CD 8+ T cells also secrete IL-2. IL-2 can enhance cytolytic activity, drive the development of Treg cells, inhibit the response of immune cells, and promote potential cell elimination function by inducing cell death through activation. In addition, IL-2 can also promote the differentiation of various effector T cell populations. Therefore, IL-2 is increasingly used in clinical practice, such as the treatment of patients with melanoma, renal cell carcinoma and other types of tumors. Therefore, in the cell culture process in the field of cell therapy, IL-2 is usually added to promote the proliferation of T cells. The residual detection of IL-2 is also a crucial link in the quality control (QC) of T cell-related products.

[0005] At present, the reagents for quantitative detection of IL-2 using antibodies generally have problems such as instability, large coefficient of variation between plates, and interference between different matrices. Therefore, it is of great significance to develop IL-2 antibodies and detection reagents with excellent specificity, affinity, and quantitative detection performance. Summary of the invention

[0006] The present invention provides antibodies specifically binding to IL-2 and applications thereof.

[0007] Specifically, the present invention provides the following technical solutions.

[0008] In a first aspect, the present invention provides an antibody or an antigen-binding fragment thereof against IL-2, wherein the antibody or the antigen-binding fragment thereof is any one of the following (1)-(2):

[0009] (1) The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 1, 2 and 3, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 4, the amino acid sequence of CDR2 is DAS, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 5;

[0010] (2) The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 6, 7 and 8, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 9, the amino acid sequence of CDR2 is KDS, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 10.

[0011] The IL-2 antibody or its antigen-binding fragment having the above-mentioned heavy chain variable region CDR and light chain variable region CDR can specifically bind to IL-2, has no cross-reaction with other cytokines such as interleukins, and has a high affinity for IL-2. When applied to the quantitative detection of IL-2, it can achieve high sensitivity, specificity, accuracy and stability, and is not affected by matrix interference.

[0012] Preferably, the antibody or antigen-binding fragment thereof is any one of the following (1)-(2):

[0013] (1) the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 11; the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 12;

[0014] (2) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 13; the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 14.

[0015] Preferably, the antibody or antigen-binding fragment thereof is selected from a monoclonal antibody, Fab, Fab', F(ab')2, Fv, a single-chain antibody, an animal-derived antibody, a chimeric antibody, a humanized antibody, a bispecific antibody or a multispecific antibody.

[0016] In some embodiments of the present invention, an antibody with clone number 6B7D7 is provided, wherein the amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 1, 2, and 3, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 4, the amino acid sequence of CDR2 is DAS, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 5. The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 11; and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 12.

[0017] In some embodiments of the present invention, an antibody with clone number 5G2B6 is provided, wherein the amino acid sequences of the complementary determining regions CDR1, CDR2, and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 6, 7, and 8, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 9, the amino acid sequence of CDR2 is KDS, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 10. The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 13; and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 14.

[0018] The IL-2 antibody or antigen-binding fragment thereof provided by the present invention can specifically bind to IL-2, has no cross-reaction with other cytokines such as interleukins, has a high affinity for IL-2, can achieve IL-2 detection with high sensitivity, specificity, accuracy and stability, and is not affected by matrix interference.

[0019] In a second aspect, the present invention provides a nucleic acid molecule encoding the above-mentioned IL-2 antibody or antigen-binding fragment thereof.

[0020] According to the amino acid sequence of the above-mentioned antibody or its antigen-binding fragment, those skilled in the art can obtain the nucleotide sequence of the nucleic acid molecule encoding the above-mentioned antibody or its antigen-binding fragment. Due to the degeneracy of codons, the nucleotide sequence of the nucleic acid molecule encoding the above-mentioned antibody or its antigen-binding fragment is not unique, and all nucleic acid molecules capable of encoding and producing the above-mentioned antibody or its antigen-binding fragment are within the protection scope of the present invention.

[0021] In a third aspect, the present invention provides a biological material, which contains the nucleic acid molecule described above; the biological material is an expression cassette, a vector or a host cell.

[0022] The above-mentioned expression cassette can be obtained by connecting a transcription or translation regulatory element such as a promoter upstream of the nucleic acid molecule and / or connecting a transcription or translation regulatory element such as a terminator downstream thereof.

[0023] The above-mentioned vectors include but are not limited to plasmid vectors, phage vectors, virus vectors, artificial chromosome vectors and the like.

[0024] The above-mentioned host cells include microbial cells, insect cells or other animal cells.

[0025] In a fourth aspect, the present invention provides an antibody conjugate, which is obtained by conjugating the IL-2 antibody or its antigen-binding fragment with a marker, wherein the marker is selected from one or more of an enzyme label, a biotin label, a fluorescent dye label, a chemiluminescent dye label, and a radioactive label.

[0026] In a fifth aspect, the present invention provides an IL-2 antibody composition, wherein the antibody composition comprises the antibodies of (1) and (2):

[0027] (1) The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 1, 2 and 3, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 4, the amino acid sequence of CDR2 is DAS, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 5;

[0028] (2) The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 6, 7 and 8, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 9, the amino acid sequence of CDR2 is KDS, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 10.

[0029] The antibodies in (1) and (2) above bind to specific spatial epitopes of the IL-2 antigen, respectively.

[0030] The above antibody composition can be used as a paired antibody for detecting IL-2 by double antibody sandwich ELISA (enzyme-linked immunosorbent assay), and the two antibodies in the antibody composition are used as the capture antibody and the detection antibody in the double antibody sandwich ELISA, respectively. The detection antibody may also carry a detectable label.

[0031] In a sixth aspect, the present invention provides a detection kit, which comprises the above-mentioned IL-2 antibody or antigen-binding fragment thereof, or comprises the antibody conjugate, or comprises the IL-2 antibody composition.

[0032] The above kit is a detection kit for IL-2. In some embodiments of the present invention, the detection kit is an ELISA detection kit, preferably a double antibody sandwich ELISA detection kit. The kit has the advantages of simple operation, high sensitivity, high specificity, high accuracy, high precision, etc., and can be used to accurately and quickly detect the content of IL-2.

[0033] Based on the antibody or its antigen-binding fragment or antibody conjugate or antibody composition of the present invention, the double antibody sandwich ELISA method can specifically detect the content of IL-2 in samples such as culture fluid, serum, plasma, cell products, etc., with high sensitivity, specificity, accuracy and stability.

[0034] In the above kit, the antibody or antigen-binding fragment thereof may further include a detectable label; the kit may further include a second antibody carrying a detectable label to detect the antibody or antigen-binding fragment thereof.

[0035] To facilitate detection, the kit may also contain other reagents for ELISA detection, including but not limited to IL-2 standard, PBST washing solution, blocking solution, color development solution, stop solution, etc.

[0036] In a seventh aspect, the present invention provides any of the following uses of the IL-2 antibody or antigen-binding fragment thereof, the nucleic acid molecule, the biomaterial, the antibody conjugate, the antibody composition, or the detection kit:

[0037] (1) Use in detecting the presence or level of IL-2 in a sample for non-disease diagnosis purposes;

[0038] (2) Use in the preparation of a product for detecting the presence or level of IL-2 in a sample;

[0039] (3) Application in the detection of IL-2 residues in cell products;

[0040] (4) Application in the production of cell products;

[0041] (5) Application in quality control of cell products.

[0042] In the above (1), the application includes using the antibody or its antigen-binding fragment or the antibody conjugate or the antibody composition or the detection kit to detect the presence or level of IL-2 in a sample. In the detection for non-disease diagnosis purposes, the sample can be a cell culture fluid obtained by in vitro culture, a cell product, or other sample that is not derived from humans or animals.

[0043] The method for detecting IL-2 using the antibody or its antigen-binding fragment, the antibody conjugate, the antibody composition, or the detection kit can use detection methods such as enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay, radioimmunoassay, fluorescent immunoassay, and immunochromatography.

[0044] In some embodiments of the present invention, the antibody or antigen-binding fragment thereof, antibody conjugate, antibody composition or detection kit is used to detect IL-2 by double antibody sandwich ELISA method.

[0045] In the above (2), the product may be a detection reagent or kit for non-diagnostic purposes or a detection reagent or kit for diagnostic purposes.

[0046] In the above (3), the residual detection of IL-2 in the cell product is to detect the presence or level of IL-2 in the cell product using the antibody or its antigen-binding fragment or the antibody conjugate or the antibody composition or the detection kit.

[0047] In the above (4), the antibody or its antigen-binding fragment, the antibody conjugate, the antibody composition or the detection kit is used to detect the IL-2 content in the cell product production process or the finished cell product.

[0048] In the above (5), the quality of the cell product is controlled by detecting the content of IL-2 in the cell product.

[0049] In an eighth aspect, the present invention provides a method for detecting IL-2 for non-disease diagnosis purposes, the method comprising: using the IL-2 antibody or its antigen-binding fragment or the antibody conjugate or the IL-2 antibody composition or the detection kit to detect IL-2 in a sample to be tested.

[0050] The above-mentioned detection can adopt enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay, radioimmunoassay, fluorescent immunoassay, immunochromatography and other detection methods.

[0051] In the present invention, the IL-2 is human IL-2.

[0052] The beneficial effects of the present invention include at least: the antibody provided by the present invention can specifically bind to IL-2, has no cross-reaction with other cytokines such as interleukins, and has a high affinity for IL-2, can achieve high specificity, high sensitivity, high accuracy, high precision and high stability detection of IL-2, performs excellently in the quantitative detection of IL-2, and is an ideal antibody for detecting IL-2 content.

[0053] Based on the above antibodies, the present invention has developed an IL-2 detection kit, which can realize the quantitative detection of IL-2 in different matrix samples, is not interfered by the matrix, has high sensitivity, specificity, accuracy and precision, is simple and fast to operate, and has low cost. It can be used for the production of T cells and the residual detection of IL-2 in the CAR-T cell process, which is conducive to promoting the application of cell gene therapy (CGT). BRIEF DESCRIPTION OF THE DRAWINGS

[0054] In order to more clearly illustrate the technical solutions in the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0055] Figure 1 This is the standard curve for detecting the content of IL-2 by the double antibody sandwich ELISA method in Example 4 of the present invention. DETAILED DESCRIPTION

[0056] In a specific embodiment of the present invention, mice are immunized with human IL-2 protein constructed in vitro as an immunogen, and hybridoma cell lines expressing antibodies are obtained through cell fusion and screening, and hybridoma cell subcloning. Experimental verification found that the antibodies obtained by screening can specifically recognize human IL-2 protein and do not cross-react with other cytokines (such as IL-7, IL-15, IL-6, IL-10, IL-21, GM-CSF, TNF-alpha, etc.). Further, the amino acid sequence of the antibody and the nucleotide sequence of its encoding gene were obtained by hybridoma sequencing.

[0057] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0058] Example 1 Preparation of Antibodies Specific to Human IL-2

[0059] In this example, the preparation process of the antibody that specifically binds to human IL-2 is as follows.

[0060] 1. Mouse immunization: Human IL-2 protein (purchased from Acrobiosystems) was used as an immunogen to immunize mice. After immunization, the serum of the immunized animals was tested by ELISA to determine the level of immune response. After conventional immunization, if the immunized animals can reach the level of immune response to the immunogen, cell fusion can be performed.

[0061] 2. Screening: Use ELISA to screen the supernatant of fusion cells and select cells that are positive for specific binding to human IL-2 protein and have no binding to IL-7, IL-15, IL-6, IL-10, IL-21, GM-CSF, TNF-alpha protein, etc.

[0062] 3. Clone expansion and cryopreservation: Transfer the positive mother clone cells to a 24-well plate for expansion and culture. Collect the supernatant of each expanded clone for detection by indirect ELISA method.

[0063] 4. Subcloning: Subclone the positive mother clones by limiting dilution method, and screen the subclones by ELISA method. The supernatant of subclone cells is screened by biolayer interferometry (BLI) method to select cells with high affinity for human IL-2 protein.

[0064] 5. Hybridoma cell antibody gene sequencing: Extract total RNA from hybridoma cells, reverse transcribe RNA into cDNA through RT-PCR reaction. Clone antibody light chain and heavy chain sequences, construct antibody light chain and heavy chain sequences onto T vectors, and then perform DNA sequencing analysis to obtain antibody gene sequences.

[0065] 6. Antibody production and purification: The antibody gene sequence obtained in step 5 was transfected into HEK293 cells and cultured. The antibody was purified by protein A / G affinity chromatography and stored in phosphate buffered saline (PBS) by dialysis.

[0066] Example 2 Specificity analysis of human IL-2 antibodies

[0067] According to the method of Example 1 above, cell culture supernatants of 10 hybridoma cells were obtained by cell fusion and screening, and the specificity of the human IL-2 antibody was analyzed by enzyme-linked immunosorbent assay. The method and results are as follows.

[0068] 1. Dilute IL-7, IL-15, IL-6, IL-10, IL-21, GM-CSF, and TNF-alpha proteins to 2 μg / mL with PBS, add 100 μL to each well of the ELISA plate. Seal the plate with a sealing film and place at 4°C overnight.

[0069] 2. Discard the liquid in the wells, pat the ELISA plate dry, wash the plate with PBST solution, 300 μL / well, soak for 30 seconds, pat the ELISA plate dry, and proceed to the next wash. Wash the plate 3 times in total.

[0070] 3. Add 100 μL of blocking agent (PBST containing 5% BSA) to each well, seal the plate with a sealing film, incubate at 37°C, and then wash.

[0071] 4. Add the cell culture supernatants of the above different clones to the ELISA plate, 100 μL per well. Seal the plate with a sealing film, incubate at 37°C, and then wash.

[0072] 5. Dilute HRP-Anti-Mouse IgG to 0.05 μg / mL with sample diluent, add 100 μL to each well, seal the plate with sealing film, incubate at 37°C, and then wash.

[0073] 6. Add 100 μL of color developing solution to each well, seal the plate with a sealing film, and incubate at 37°C away from light.

[0074] 7. Add 50 μL of stop solution to each well and gently shake the ELISA plate until the color is evenly developed.

[0075] 8. Use an ELISA reader to read the absorbance at 450nm and 630nm, and use OD 450 Deduction OD 630 The absorbance value (OD value) was obtained, and the test results are shown in Table 1.

[0076] 9. Select clones that strongly bind to human IL-2 protein and do not bind to IL-7, IL-15, IL-6, IL-10, IL-21, GM-CSF and TNF-alpha proteins. The selected clones include 1A10B1, 3D5B2, 2D1C10, 2D12C9, 3F10A12, 4F9G6, 2F8E2, 3D6F8, 5G2B6, and 6B7D7. The antibodies of these clones strongly bind to human IL-2 protein and have no cross-reaction with other cytokines (Table 1).

[0077] Table 1 ELISA OD values ​​of supernatants from different clones

[0078]

[0079] Example 3 Affinity Analysis of Human IL-2 Antibodies

[0080] After subcloning the 10 clones selected in Example 2, 10 cell supernatants were obtained, and the affinity of the monoclonal antibodies produced by the 10 clones was analyzed using BLI technology. The analysis method and results are described as follows.

[0081] 1. Run the AMC biosensor in the first column in 1× PBS solution (pH 7.4) containing 0.02% Tween-20 and 0.1% BSA for 60 seconds. This step is the baseline step.

[0082] 2. Run the sensor in the cell supernatant of the above different clones for a period of time until it is solidified on the sensor for 200s.

[0083] 3. The biosensor was run in a 1× PBS solution (pH 7.4) containing 0.02% Tween-20 and 0.1% BSA for 60 seconds. This step was the baseline step.

[0084] 4. Dilute the IL-2 protein to 200 nM with 1× PBS solution (pH 7.4) containing 0.02% Tween-20 and 0.1% BSA. Run the sensor for 60 seconds. During this process, antibodies of different clones on the sensor will be able to bind to the IL-2 protein.

[0085] 5. The sensor was run in a 1× PBS solution (pH 7.4) containing 0.02% Tween-20 and 0.1% BSA for 90 seconds, during which the IL-2 protein was dissociated from the sensor.

[0086] 6. The sensor was regenerated in 10 mM Glycine-HCl solution (pH 1.5) for 5 s, and then neutralized in 1× PBS solution (pH 7.4) containing 0.02% Tween-20 and 0.1% BSA for 5 s. The regeneration was repeated three times.

[0087] The test results are shown in Table 2, which show that all 10 antibodies have high affinity to human IL-2.

[0088] Table 2 Affinity values ​​of different antibodies detected by BLI

[0089]

[0090] Example 4 Identification and functional analysis of human IL-2 specific antibodies

[0091] The sensitivity of the 10 human IL-2 antibodies in Examples 2 and 3 was analyzed by double antibody sandwich ELISA and chessboard method, and finally two antibodies with higher sensitivity (clone number: 6B7D7, 5G2B6) were screened out. The sensitivity of the two antibody pairing for IL-2 detection was 39.06pg / mL, which was significantly higher than the sensitivity of the other clone number antibody pairings.

[0092] Furthermore, a double antibody sandwich ELISA method was used to perform a quantitative detection experiment of human IL-2 using antibodies with clone numbers 6B7D7 and 5G2B6, wherein 6B7D7 was a coating antibody and 5G2B6 was a detection antibody. The details are as follows.

[0093] 1. Results of quantitative detection of human IL-2 ( Figure 1 ) showed that the double antibody sandwich ELISA method could be used to quantitatively detect human IL-2 using antibodies with clone numbers 6B7D7 and 5G2B6, thereby obtaining the content of IL-2 protein in the matrix with good linear correlation.

[0094] 2. The results of the human IL-2 quantitative detection experiment (Table 3) showed that the quantitative detection of human IL-2 by double antibody sandwich ELISA method using antibodies with clone numbers 6B7D7 and 5G2B6 was not interfered by the matrix.

[0095] Table 3 Recovery rate of IL-2 detected by double antibody sandwich ELISA in different matrices

[0096]

[0097] 3. The methodological validation results of the double antibody sandwich ELISA method for quantitative detection of human IL-2 using antibodies with clone numbers 6B7D7 and 5G2B6 (Table 4) showed that this quantitative detection method has high accuracy, high precision, and good stability, and can accurately and quickly quantify IL-2 protein in the matrix.

[0098] Table 4 Validation results of human IL-2 quantitative detection methodology

[0099]

[0100] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. An antibody or antigen-binding fragment thereof against IL-2, characterized in that: The antibody or antigen-binding fragment thereof is any one of the following (1)-(2): (1) The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 1, 2 and 3, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 4, the amino acid sequence of CDR2 is DAS, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 5; (2) The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 6, 7 and 8, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 9, the amino acid sequence of CDR2 is KDS, and the amino acid sequence of CDR3 is shown in SEQ ID NO:

10.

2. The IL-2 antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody or antigen-binding fragment thereof is any one of the following (1)-(2): (1) the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 11; the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 12; (2) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 13; the amino acid sequence of the light chain variable region is shown in SEQ ID NO:

14.

3. The IL-2 antibody or antigen-binding fragment thereof according to claim 1 or 2, characterized in that: The antibody or antigen-binding fragment thereof is selected from monoclonal antibody, Fab, Fab', F(ab')2, Fv, single-chain antibody, animal-derived antibody, chimeric antibody, humanized antibody, bispecific antibody or multispecific antibody.

4. A nucleic acid molecule, characterized in that The antibody or antigen-binding fragment thereof encodes the IL-2 according to any one of claims 1 to 3.

5. Biomaterial, characterized in that It contains the nucleic acid molecule according to claim 4, and the biological material is an expression cassette, a vector or a host cell.

6. An antibody conjugate, characterized in that: The IL-2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3 is coupled with a label, wherein the label is selected from one or more of enzyme labeling, biotin labeling, fluorescent dye labeling, chemiluminescent dye labeling, and radioactive labeling.

7. An IL-2 antibody composition, characterized in that The antibody composition comprises the following antibodies (1) and (2): (1) The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 1, 2 and 3, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 4, the amino acid sequence of CDR2 is DAS, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 5; (2) The amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NOs: 6, 7 and 8, respectively; the amino acid sequence of the complementary determining region CDR1 of the light chain variable region is shown in SEQ ID NO: 9, the amino acid sequence of CDR2 is KDS, and the amino acid sequence of CDR3 is shown in SEQ ID NO:

10.

8. A detection kit, characterized in that: It comprises the IL-2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, or the antibody conjugate according to claim 6, or the IL-2 antibody composition according to claim 7.

9. Any of the following uses of the IL-2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, the nucleic acid molecule according to claim 4, the biomaterial according to claim 5, the antibody conjugate according to claim 6, the IL-2 antibody composition according to claim 7, or the detection kit according to claim 8: (1) Use in detecting the presence or level of IL-2 in a sample for non-disease diagnosis purposes; (2) Use in the preparation of a product for detecting the presence or level of IL-2 in a sample; (3) Application in the detection of IL-2 residues in cell products; (4) Application in the production of cell products; (5) Application in quality control of cell products.

10. A method for detecting IL-2 for non-disease diagnosis purposes, characterized in that: The method comprises: using the IL-2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, the antibody conjugate according to claim 6, the IL-2 antibody composition according to claim 7, or the detection kit according to claim 8 to detect IL-2 in the sample to be tested.